Nektar Therapeutics (NKTR) CEO granted 57,200 options with $15.15 strike
Rhea-AI Filing Summary
Howard W. Robin, President & CEO of Nektar Therapeutics, reported an acquisition of 57,200 stock options linked to common stock. These options were granted on December 13, 2024 under the 2017 Amended and Restated Performance Incentive Plan, have a $15.15 exercise price, and expire on December 12, 2032. The Organization and Compensation Committee determined on July 23, 2026 that the performance-based vesting requirement was satisfied and stated that the options vested on July 24, 2026, while time-based vesting continues on a monthly pro-rata basis over five years from the grant date.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
ROBIN HOWARD W
Role
President & CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option F1, F2 | 57,200 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option — 57,200 shares (Direct)
Footnotes (2)
- F1. These stock options were granted on December 13, 2024 under the 2017 Amended and Restated Performance Incentive Plan and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a monthly pro-rata basis over a period of five years from the date of grant.
- F2. The Organization and Compensation Committee of the Board of Directors of the Issuer determined on July 23, 2026 that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on July 24, 2026 (subject to remaining time-based vesting requirements).
Key Figures
Stock options acquired: 57,200 options
Exercise price: $15.15 per share
Expiration date: December 12, 2032
+4 more
7 metrics
Stock options acquired
57,200 options
Grant, award, or other acquisition of derivative securities linked to common stock
Exercise price
$15.15 per share
Conversion or exercise price of the stock options
Expiration date
December 12, 2032
Expiry of the reported stock options
Grant date
December 13, 2024
Date the options were granted under the 2017 Amended and Restated Performance Incentive Plan
Performance vesting satisfaction date
July 23, 2026
Committee determined performance-based vesting requirement was satisfied
Vesting date referenced
July 24, 2026
Stock options stated to have vested, subject to remaining time-based vesting requirements
Time-based vesting period
5 years
Monthly pro-rata vesting over five years from the grant date
Key Terms
performance-based vesting requirement, time-based vesting, 2017 Amended and Restated Performance Incentive Plan, Organization and Compensation Committee
4 terms
performance-based vesting requirement financial
"the performance-based vesting requirement for these stock options was satisfied"
time-based vesting financial
"The time-based vesting is on a monthly pro-rata basis over a period"
Time-based vesting is a schedule that gives employees or contractors ownership of granted stock or options gradually as they remain with a company, like unlocking rewards in a loyalty program the longer you stick around. For investors, it matters because it affects future share supply, management incentives and staff retention — all of which can influence company performance and dilution of existing shareholders.
2017 Amended and Restated Performance Incentive Plan financial
"These stock options were granted on December 13, 2024 under the 2017 Amended"
Organization and Compensation Committee financial
"The Organization and Compensation Committee of the Board of Directors"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Nektar Therapeutics (NKTR) report for Howard W. Robin?
Nektar Therapeutics reported that President & CEO Howard W. Robin acquired 57,200 stock options linked to common stock, recorded as a grant or award acquisition on July 24, 2026, under the company’s 2017 Amended and Restated Performance Incentive Plan.
How many stock options did the Nektar (NKTR) CEO receive and at what exercise price?
Howard W. Robin holds 57,200 stock options with an exercise price of $15.15 per share. These derivative securities relate to an equal number of shares of Nektar Therapeutics common stock and are reported as directly owned following the transaction.
What are the vesting terms of the CEO’s stock options reported by NKTR?
The options were granted with both performance-based and time-based vesting. Time-based vesting occurs on a monthly pro-rata basis over five years from the December 13, 2024 grant date, and performance-based conditions were later determined to be satisfied.
When were the performance-based conditions for Nektar (NKTR) CEO options satisfied and vested?
The Organization and Compensation Committee determined on July 23, 2026 that the performance-based requirement was satisfied, and stated that the 57,200 stock options vested on July 24, 2026, subject to remaining time-based vesting requirements continuing over the five-year schedule.
When do the Nektar Therapeutics (NKTR) CEO stock options expire?
The 57,200 stock options held by Howard W. Robin expire on December 12, 2032. They were granted on December 13, 2024 and carry a $15.15 exercise price, providing a defined window for potential future exercise of these derivative securities.
Were Howard W. Robin’s Nektar (NKTR) option transactions under a Rule 10b5-1 plan?
The filing’s Rule 10b5-1 checkbox is not marked as being pursuant to such a plan, indicating these reported option-related events are not affirmed as made under a pre-arranged Rule 10b5-1 trading arrangement in this disclosure.